OVCAR-4 Cells
US$ 650,00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Informações gerais
| Descrição | OVCAR-4 is a human ovarian carcinoma cell line derived from an adult patient with epithelial ovarian cancer who had previously undergone combination chemotherapy. It belongs to a panel of ovarian cancer cell lines established to model clinical drug resistance and tumor heterogeneity. As part of this series, OVCAR-4 reflects characteristics of tumors exposed to chemotherapeutic agents such as cisplatin and doxorubicin, making it particularly valuable for studying mechanisms of chemotherapy response and resistance. Molecular analyses have demonstrated that OVCAR-4 exhibits detectable expression of metallothionein mRNA, a protein involved in metal ion binding and cellular detoxification pathways. Notably, exposure to cisplatin induces only a modest increase in metallothionein expression in this cell line, suggesting that while metallothionein may contribute to cellular stress responses, it is not a primary determinant of cisplatin resistance in this model. These findings highlight the complexity of drug resistance mechanisms in ovarian cancer, where multiple pathways—including drug transport, DNA repair, and intracellular detoxification - may act in parallel. OVCAR-4 is included in the NCI-60 cancer cell line panel and has been utilized in high-content phenotypic profiling studies. Fluorescence-based screening approaches have shown that OVCAR-4 exhibits distinct intracellular staining patterns and intensity kinetics when exposed to diverse fluorescent probes, enabling its classification alongside other ovarian cancer cell lines. These phenotypic signatures reflect underlying biochemical and morphological features, supporting the use of OVCAR-4 in systems biology, drug screening, and cancer cell lineage identification studies. |
|---|---|
| Organismo | Human |
| Tecido | Metastatic |
| Doença | High grade ovarian serous adenocarcinoma |
| Local da metástase | Ascites |
| Sinônimos | OVCAR 4, NIH:OVCAR-4, NIH:OVCAR4, OVCAR.4, OVCAR4, Ovcar4 |
Características
| Idade | 42 years |
|---|---|
| Gênero | Female |
| Etnia | Caucasian |
| Propriedades de crescimento | Adherent |
Dados regulatórios
| Referência | OVCAR-4 (Cytion catalog number 305912) |
|---|---|
| Nível de biossegurança | 1 |
| NCBI_TaxID | 9606 |
| Número de acesso do Cellosaurus | CVCL_1627 |
Dados biomoleculares
| Perfil mutacional | Mutation: p.Leu130Val, Homozygous |
|---|
Manuseio
| Meio de cultura | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 20% FBS and 0.25 units/mL human insulin |
| Reagente de dissociação | Accutase |
| Tempo de duplicação | 34 hours ; 43 hours ; 41.4 hours |
| Densidade de semeadura | 1.5 to 3 x 104 cells/cm2 |
| Renovação de fluidos | 2 to 3 times per week |
| Meio de congelamento | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelamento e cultura de células |
|
| Atmosfera de incubação | 37°C, 5% CO2, humidified atmosphere. |
| Condições de envio | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condições de armazenamento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Controle de Qualidade e Análise Molecular
| Local da metástase: | Ascites |
|---|
Certificado de Análise (CoA)
| Número do lote | Tipo de certificado | Data | Número de catálogo |
|---|---|---|---|
| 305912-040326 | Certificado de Análise | 31. Mar. 2026 | 305912 |